IP Library Patent Application 11542291
Patent Application
App. No. 11/542,291

Methods and compositions for silencing genes without inducing toxicity

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/542,291
Abstract

The present invention provides methods of post-transcriptional gene silencing which involve the use of a first dsRNA having substantial sequence identity to a target nucleic acid and a short, second dsRNA which inhibits dsRNA-mediated toxicity. These methods can be used to prevent or treat a disease or infection by silencing a gene associated with the disease or infection. The invention also provides methods for identifying nucleic acid sequences that modulate a detectable phenotype, including the function of a cell, the expression of a gene, or the biological activity of a target polypeptide.

Claims (45)

1 . A method for inhibiting the expression of a target nucleic acid in a cell, said method comprising introducing into said cell a first agent that provides to said cell a first double stranded RNA (dsRNA) and a second agent that provides to said cell a short, second dsRNA, wherein said first dsRNA has substantial sequence identity to a region of said target nucleic acid and specifically inhibits said expression of said target nucleic acid, and wherein said short, second dsRNA inhibits dsRNA-mediated toxicity.

2 . The method of claim 1 , wherein the double stranded region in said second dsRNA contains between 11 and 30 nucleotides, inclusive.

3 . The method of claim 1 , wherein the double stranded region in said first dsRNA contains between 11 and 30 nucleotides, inclusive.

4 . The method of claim 1 , wherein the double stranded region in said first dsRNA contains over 30 nucleotides.

5 . The method of claim 4 , wherein the double stranded region in said first dsRNA contains over 200 nucleotides.

6 . The method of claim 1 , wherein said first and/or second agent is a nucleic that encodes a dsRNA.

7 . The method of claim 1 , wherein said cell is a vertebrate cell.

8 . The method of claim 1 , wherein said cell is a mammalian cell.

9 . The method of claim 8 , wherein said cell is a human cell.

10 . A method for inhibiting the expression of a target nucleic acid in an animal, said method comprising introducing into said animal a first agent that provides to said animal a first dsRNA and a second agent that provides to said animal a short, second dsRNA, wherein said first dsRNA has substantial sequence identity to region of said target nucleic acid and specifically inhibits said expression of said target nucleic acid, and wherein said short, second dsRNA inhibits dsRNA-mediated toxicity.

11 . The method of claim 10 , wherein the double stranded region in said second dsRNA contains between 11 and 30 nucleotides, inclusive.

12 . The method of claim 10 , wherein the double stranded region in said first dsRNA contains between 11 and 30 nucleotides, inclusive.

13 . The method of claim 10 , wherein the double stranded region in said first dsRNA contains over 30 nucleotides.

14 . The method of claim 13 , wherein the double stranded region in said first dsRNA contains over 200 nucleotides.

15 . The method of claim 10 , wherein said first and/or second agent is a nucleic acid that encodes a dsRNA.

16 . The method of claim 10 , wherein said animal is a vertebrate.

17 . The method of claim 10 , wherein said animal is a mammal.

18 . The method of claim 17 , wherein said animal is a human.

19 . A method for treating, stabilizing, or preventing a disease, disorder, or infection in an animal, said method comprising introducing into said animal a first agent that provides to said animal a first dsRNA and a second agent that provides to said animal a short, second dsRNA, wherein said first dsRNA has substantial sequence identity to a region of a target nucleic acid associated with said disease, disorder, or infection and specifically inhibits said expression of said target nucleic acid, and wherein said short, second dsRNA inhibits dsRNA-mediated toxicity.

20 . The method of claim 19 , wherein the double stranded region in said second dsRNA contains between 11 and 30 nucleotides, inclusive.

21 . The method of claim 19 , wherein the double stranded region in said first dsRNA contains between 11 and 30 nucleotides, inclusive.

22 . The method of claim 19 , wherein the double stranded region in said first dsRNA contains over 30 nucleotides.

23 . The method of claim 22 , wherein the double stranded region in said first dsRNA contains over 200 nucleotides.

24 . The method of claim 19 , wherein said first and/or second agent is a nucleic acid that encodes a dsRNA.

25 . The method of claim 19 , wherein said animal is a vertebrate.

26 . The method of claim 19 , wherein said animal is a mammal.

27 . The method of claim 26 , wherein said animal is a human.

28 . The method of claim 19 , wherein said target nucleic acid is associated with a pathogen.

29 . The method of claim 28 , wherein said pathogen is a virus, bacterium, yeast, or infectious agent.

30 . A method for identifying a nucleic acid that modulates a detectable phenotype in a cell, said method comprising said steps of:

(a) transforming a population of cells with a dsRNA expression library, wherein at least two cells of said population of cells are each transformed with a different nucleic acid from said dsRNA expression library;

(b) transforming said cells with a short dsRNA or a nucleic acid encoding a short dsRNA; and

(c) assaying for a modulation in said detectable phenotype, wherein said modulation identifies a nucleic acid that is associated with said phenotype.

31 . The method of claim 30 , wherein said modulation in a detectable phenotype is a modulation in the function of a cell, a modulation in the biological activity of a polypeptide, or a modulation in the expression of a target nucleic acid.

32 . The method of claim 30 , further comprising:

(d) identifying said nucleic acid by amplifying said nucleic acid and sequencing said amplified nucleic acid.

33 . The method of claim 30 , wherein said dsRNA expression library comprises cDNAs derived from said cells.

34 . The method of claim 30 , wherein the double stranded region in said second dsRNA contains between 11 and 30 nucleotides, inclusive.

35 . The method of claim 30 , wherein the double stranded region in said first dsRNA or said dsRNA encoded by said library contains between 11 and 30 nucleotides, inclusive.

36 . The method of claim 30 , wherein the double stranded region in said first dsRNA or said dsRNA encoded by said library contains over 30 nucleotides.

37 . The method of claim 36 , wherein the double stranded region in said first dsRNA or said dsRNA encoded by said library contains over 200 nucleotides.

38 . The method of claim 30 , wherein said first and/or second agent is a nucleic acid which encodes a dsRNA.

39 . The method of claim 30 , wherein said cell is a vertebrate cell.

40 . The method of claim 30 , wherein said cell is a mammalian cell.

41 . The method of claim 40 , wherein said cell is a human cell.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2009
From: NUCLEONICS, INC.
To: ALNYLAM PHARMACEUTICALS, INC.
Reel/Frame 022386/0468 →
RELEASE OF SECURITY INTEREST Recorded Dec 5, 2008
From: NEW ENTERPRISE ASSOCIATES 10, LIMITED PARTNERSHIP; BURRILL LIFE SCIENCES CAPITAL FUND, L.P.; BURRILL INDIANA LIFE SCIENCES CAPITAL FUND, L.P.; OFCO CLUB IV; HEALTHCAP IV KB; HEALTHCAP IV, L.P.; HEALTHCAP IV BIS, L.P.; S.R. ONE, LIMITED; QUAKER BIOVENTURES, L.P.; QUAKER BIOVENTURES TOBACCO FUND, L.P.; POSCO BIOVENTURES I, L.P.
To: NUCLEONICS, INC.
Reel/Frame 021932/0001 →
SECURITY AGREEMENT Recorded Sep 29, 2008
From: NUCLEONICS, INC.
To: NEW ENTERPRISE ASSOCIATES 10, LIMITED PARTNERSHIP; S.R. ONE, LIMITED; OFCO CLUB IV; HEALTHCAP IV KB; HEALTHCAP IV, L.P.; HEALTHCAP IV BIS, L.P.; BURRILL LIFE SCIENCES CAPITAL FUND, L.P.; BURRILL INDIANA LIFE SCIENCES CAPITAL FUND, L.P.; QUAKER BIOVENTURES, L.P.; QUAKER BIOVENTURES TOBACCO FUND, L.P.; POSCO BIOVENTURES I, L.P.
Reel/Frame 021602/0423 →